TDP‐43 as structure‐based biomarker in amyotrophic lateral sclerosis. Issue 1 (2nd December 2020)

• Record Type: Journal Article
• Authors: Beyer, Léon; Günther, René; Koch, Jan Christoph; Klebe, Stephan; Hagenacker, Tim; Lingor, Paul; Biesalski, Anne‐Sophie; Hermann, Andreas; Nabers, Andreas; Gold, Ralf; Tönges, Lars; Gerwert, Klaus
• Is Part Of: Annals of clinical and translational neurology. Volume 8:Issue 1(2021)
• Page Start: 271
• Page End: 277
• Publication Date: 2020-12-02
• Subjects: Nervous system -- Diseases -- Periodicals; Neurology -- Periodicals; 616.8005
• DOI: 10.1002/acn3.51256
• Languages: English
• ISSNs: 2328-9503

Abstract

Abstract: Pathologic alterations of Transactivation response DNA‐binding protein 43 kilo Dalton (TDP‐43) are a major hallmark of amyotrophic lateral sclerosis (ALS). In this pilot study, we analyzed the secondary structure distribution of TDP‐43 in cerebrospinal fluid of ALS patients ( n = 36) compared to Parkinson´s disease patients (PD; n = 30) and further controls (Ctrl; n = 24) using the immuno‐infrared sensor technology. ALS patients could be discriminated from PD and Ctrl with a sensitivity/specificity of 89 %/77 % and 89 %/83 %, respectively. Our findings demonstrate that TDP‐43 misfolding measured by the immuno‐infrared sensor technology has the potential to serve as a biomarker candidate for ALS.